Published in
American Society of Hematology, Blood Advances, 20(3), p. 3052-3061, 2019
DOI: 10.1182/bloodadvances.2019000197
Links
Tools
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia
Journal article published in 2019 by
Paul Milne 
,
Charlotte Wilhelm-Benartzi,
Michael R. Grunwald,
Venetia Bigley ,
Richard Dillon ,
Sylvie D. Freeman ,
Kathleen Gallagher,
Amy Publicover,
Sarah Pagan,
Helen Marr,
Gail L. Jones,
Anne M. Dickinson,
Angela Grech,
Alan K. Burnett,
Nigel H. Russell
and other authors.
,
Charlotte Wilhelm-Benartzi,
Michael R. Grunwald,
Venetia Bigley ,
Richard Dillon ,
Sylvie D. Freeman ,
Kathleen Gallagher,
Amy Publicover,
Sarah Pagan,
Helen Marr,
Gail L. Jones,
Anne M. Dickinson,
Angela Grech,
Alan K. Burnett,
Nigel H. Russell
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Flt3L is a biomarker of progenitor cell mass in AML. Measurement of Flt3L during induction chemotherapy and follow-up provides prognostic information.